Company Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1990 |
| IPO Date | May 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Howard Robin |
Contact Details
Address: 455 Mission Bay Boulevard South San Francisco, California 94158 United States | |
| Phone | 415 482 5300 |
| Website | nektar.com |
Stock Details
| Ticker Symbol | NKTR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000906709 |
| CUSIP Number | 640268108 |
| ISIN Number | US6402681083 |
| Employer ID | 94-3134940 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard W. Robin | Chief Executive Officer, President and Director |
| Sandra A. Gardiner | Chief Financial Officer and Principal Financial and Accounting Officer |
| Mark A. Wilson J.D. | Senior Vice President, Chief Legal Officer and Secretary |
| Dr. Jonathan Zalevsky Ph.D. | Senior Vice President and Chief Research and Development Officer |
| Jason Barnard | Chief Accounting Officer |
| Vivian Wu | Director of Investor Relations and Corporate Affairs |
| Robert Bacci | Chief People Officer and Head of Quality and Facilities |
| Jennifer Ruddock | Chief Business Officer |
| Dr. Brian L. Kotzin M.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 14, 2025 | DRS | [Cover] Draft Registration Statement |
| Mar 14, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 14, 2025 | 10-K | Annual Report |
| Mar 12, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 19, 2025 | 144 | Filing |
| Feb 19, 2025 | 144 | Filing |
| Feb 19, 2025 | 144 | Filing |